The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | Momelotinib: a promising agent in MF
Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the promise of momelotinib for the treatment of myelofibrosis (MF), highlighting the ability of this agent to improve anemia in patients, as well as the size of the spleen. Dr Verstovsek also comments on the potential approval of this agent in the near future and the value of adding momelotinib to the MF treatment armamentarium. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
